Periodic Reporting for period 3 - ImmUniverse (Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies)
Período documentado: 2022-01-01 hasta 2022-12-31
Regarding retrospective studies, six clinical centers have obtained ethical approval and made their samples available to the consortium. These include several biomaterials originating from both Ulcerative Colitis (UC) and Atopic Dermatitis (AD) patients and different types of –omics datasets. Analytical protocols for different types of samples and biomolecules have been developed and validated and first analyses employing retrospective samples and datasets have been performed and are currently being integrated with clinical data.
Eight clinical centers have obtained ethical approval for prospective clinical studies and recruitment is currently ongoing or due to start in early 2023. As of end 2022, 87 and 90 patients have been enrolled for UC and for AD, respectively. Due to COVID-related issues, some centers are expected to underrecruit and mitigation plans are being developed.
dOFM has been set up as non-invasive liquid biopsy technology for AD in two clinical centers sites. Patient recruitment, as well as the analysis of the first samples are in progress. All preclinical studies for LIPUS application as disruptive liquid biopsy for UC have been completed and optimal conditions and protocol for clinical translation have been defined. Study protocol has been submitted for ethical approval at the end of 2022.
ImmUniverse started to create general awareness by producing communication materials such as an animated clip and an FAQ article, both can be found on the website. Social Media campaigns are ongoing. A position paper was published by Frontiers in Immunology (https://www.frontiersin.org/articles/10.3389/fimmu.2022.1002629/full).